Endocannabinoid System and Bone Loss in Celiac Disease: Towards a Demanding Research Agenda
- PMID: 33093361
- DOI: 10.1097/MPG.0000000000002887
Endocannabinoid System and Bone Loss in Celiac Disease: Towards a Demanding Research Agenda
Comment on
-
The Role of Cannabinoid Receptor Type 2 in the Bone Loss Associated With Pediatric Celiac Disease.J Pediatr Gastroenterol Nutr. 2020 Nov;71(5):633-640. doi: 10.1097/MPG.0000000000002863. J Pediatr Gastroenterol Nutr. 2020. PMID: 33093370
References
-
- Di Stefano M, Mengoli C, Bergonzi M, et al. Bone mass and mineral metabolism alterations in adult celiac disease: pathophysiology and clinical approach. Nutrients 2013; 5:4786–4799.
-
- Di Stefano M, Bergonzi M, Benedetti I, et al. Alterations of inflammatory and matrix production indices in celiac disease with low bone mass on long-term gluten-free diet. J Clin Gastroenterol 2019; 53:e221–e226.
-
- Taranta A, Fortunati D, Longo M, et al. Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. J Bone Miner Res 2004; 19:1112–1121.
-
- Fornari MC, Pedreira S, Niveloni S, et al. Pre- and post-treatment serum levels of cytokines IL-1beta, IL-6, and IL-1 receptor antagonist in celiac disease. Are they related to the associated osteopenia? Am J Gastroenterol 1998; 93:413–418.
-
- Tortora C, Punzo F, Argenziano M, et al. The role of cannabinoid receptor type 2 in the bone loss associated with pediatric celiac disease. J Pediatr Gastroenterol Nutr 2020; 71:633–640.